Replies to post #410613 on Amarin Corp Plc (AMRN)

[Whalatane]

N7. thx for that link.
So a question for you ....and anyone else interested .
In MITIGATE Kaiser enrolled secondary prevention CAD patients ...those presumed to gain CV event risk reduction on Vascepa .
Once these patients had been prescribed Vascepa ...would Kaiser ever end that prescription unless there were signs of harm ?
Why wouldn't they have just started charging for the script .....in my case ( I'm secondary prevention and fit the profile of the MITIGATE study ) .....a copay of $2 a month.

If those prescribed Vascepa in MITIGATE had the opportunity to stay on Vascepa ( with a monthly $2 copay ) ....then Kaiser now has around 2 yrs of data on the first 1,000 enrolled ( assuming this 1,000 continued on V )

I just don't see Kaiser withdrawing the V script once prescribed to this secondary prevention CAD population
Your thoughts ? RMB and others ,any opinion ?

Kiwi